Overview

Study of Epratuzumab in Systemic Lupus Erythematosus

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Epratuzumab is an investigational antibody designed to help treat SLE. The purpose is to evaluate safety and long term efficacy in concert with standard SLE treatments
Phase:
Phase 3
Details
Lead Sponsor:
UCB Pharma
Treatments:
Epratuzumab